Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
- 11 March 2024
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 202, 114006
Abstract
No abstract availableKeywords
Funding Information
- Università Cattolica del Sacro Cuore
- Ministero della Salute
- Associazione Italiana per la Ricerca sul Cancro (IG20583)
This publication has 20 references indexed in Scilit:
- OA14.05 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%Journal of Thoracic Oncology, 2023
- Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancerLung Cancer, 2021
- Effect of corticosteroids on the outcome of patients with advanced non–small cell lung cancer treated with immune-checkpoint inhibitorsEuropean Journal of Cancer, 2021
- Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab MonotherapyClinical Lung Cancer, 2021
- Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trialThe Lancet, 2021
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996